Paul Guilhamon

Paul Guilhamon

Auto-generated profile, based on publicly available information

Paul Guilhamon

Princess Margaret Cancer Centre, University Health Network

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Nature
Verified
Journal Article
Open access
PDF file
XLXiaoyang Lan
Xiaoyang Lan
DJDavid J. Jörg
David J. Jörg
FCFlorence M. G. Cavalli
Florence M. G. Cavalli
LRLaura M. Richards
Laura M. Richards
Long NguyenLong Nguyen
Long Nguyen
PDPeter B. Dirks
Peter B. Dirks
Human glioblastomas harbour a subpopulation of glioblastoma stem cells that drive tumorigenesis. However, the origin of intratumoural functional heterogeneity between glioblastoma cells remains poorly understood. Here we study the clonal evolution of barcoded glioblastoma cells in an unbiased way following serial xenotransplantation to define their individual fate behaviours. Independent of an evolving mutational signature, we show that the growth of glioblastoma clones in vivo is consistent with a remarkably neutral process involving a conserved proliferative hierarchy rooted in glioblastoma stem cells. In this model, slow-cycling stem-like cells give rise to a more rapidly cycling progenitor population with extensive self-maintenance capacity, which in turn generates non-proliferative cells. We also identify rare ‘outlier’ clones that deviate from these dynamics, and further show that chemotherapy facilitates the expansion of pre-existing drug-resistant glioblastoma stem cells. Finally, we show that functionally distinct glioblastoma stem cells can be separately targeted using epigenetic compounds, suggesting new avenues for glioblastoma-targeted therapy.

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
JTJonathon Torchia
Jonathon Torchia
BGBrian Golbourn
Brian Golbourn
SFShengrui Feng
Shengrui Feng
KHKing Ching Ho
King Ching Ho
PSPatrick Sin-Chan
Patrick Sin-Chan
AHAnnie Huang
Annie Huang

1 May 2019 in Cancer Cell
Verified
Journal Article
Closed access
BKBrian Krug
Brian Krug
NJNicolas De Jay
Nicolas De Jay
AHAshot S. Harutyunyan
Ashot S. Harutyunyan
SDShriya Deshmukh
Shriya Deshmukh
DMDylan M. Marchione
Dylan M. Marchione
SMStephen C. Mack
Stephen C. Mack

18 July 2013 in Nature Communications
Verified
Journal Article
Open access
PGPaul Guilhamon
Paul Guilhamon
MEMalihe Eskandarpour
Malihe Eskandarpour
DHDina Halai
Dina Halai
GWGareth A. Wilson
Gareth A. Wilson
AFAndrew Feber
Andrew Feber
SBStephan Beck
Stephan Beck
Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequently mutated in acute myeloid leukaemia (AML), low-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS). For AML, low-grade glioma and CC, mutant IDH status is associated with a DNA hypermethylation phenotype, implicating altered epigenome dynamics in the aetiology of these cancers. Here we show that the IDH variants in CS are also associated with a hypermethylation phenotype and display increased production of the oncometabolite 2-hydroxyglutarate, supporting the role of mutant IDH-produced 2-hydroxyglutarate as an inhibitor of TET-mediated DNA demethylation. Meta-analysis of the acute myeloid leukaemia, low-grade glioma, cholangiocarcinoma and CS methylation data identifies cancer-specific effectors within the retinoic acid receptor activation pathway among the hypermethylated targets. By analysing sequence motifs surrounding hypermethylated sites across the four cancer types, and using chromatin immunoprecipitation and western blotting, we identify the transcription factor EBF1 (early B-cell factor 1) as an interaction partner for TET2, suggesting a sequence-specific mechanism for regulating DNA methylation.

1 August 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
NPNicole I. Park
Nicole I. Park
PGPaul Guilhamon
Paul Guilhamon
KDKinjal Desai
Kinjal Desai
RMRochelle F. McAdam
Rochelle F. McAdam
ELEllen Langille
Ellen Langille
PDPeter B. Dirks
Peter B. Dirks

1 September 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GDGeneviève Deblois
Geneviève Deblois
STSeyed Ali Madani Tonekaboni
Seyed Ali Madani Tonekaboni
GGGiacomo Grillo
Giacomo Grillo
CMConstanza Martinez
Constanza Martinez
YKYunchi Ingrid Kao
Yunchi Ingrid Kao
MLMathieu Lupien
Mathieu Lupien
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. Significance: Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC. See related commentary by Janin and Esteller, p. 1258. This article is highlighted in the In This Issue feature, p. 1241